A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 458 participants.

Also called NCT02791490

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 458 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02791490
  • EudraCT 2015-004224-59
Other papers using this trial's data
  • Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study Diabetes, obesity & metabolism, 2019-05 DOI, PubMed 30609212, PMC6593795 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02791490. Randomized; double masking; primary purpose treatment. Start 2016-06-16 (actual); primary completion 2018-02-01 (actual). Results posted on 2019-02-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo
Intervention (Drug)
Metformin IR
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct02791490
Content hash
88131fb3d8bde6c9911fea8c5da6393a4f9f1ddc92e43340fbb50a277fec9c38